我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Quanterix Corporation's HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration from South Korea's Ministry of Food and Drug Safety, expanding global access to ultrasensitive biomarker testing. - The Simoa platform enables detection of Alzheimer's disease biomarkers in blood, serum, or plasma at levels far below traditional measurement platforms' limits of quantification. - New collaborations with major laboratories including ARUP Laboratories and Rede D'Or in Brazil are strengthening infrastructure for Alzheimer's testing using phosphorylated tau 217 (P-tau217) biomarkers. - The technology addresses early detection needs as Alzheimer's disease signs may begin 20 years or more before symptoms appear, potentially improving patient access to treatments.
